Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

3.8K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
3.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Simultaneous Construction of Sulfur and Carbon Stereocenters via Asymmetric Desymmetrization of Sulfonimidamides With Oxindole Derivatives.

Angewandte Chemie (International ed. in English)·2026
Same author

Evaluating air pollution and economic impacts in Chinese megacity clusters under clean air policies.

iScience·2026
Same author

Knowledge, attitudes, and practices regarding advance care planning among emergency department healthcare providers in China: a multicenter cross-sectional study.

Frontiers in public health·2026
Same author

A Novel Technology Platform for Extracellular Vesicle-Targeted Expression of Drug-Metabolizing Enzymes: Driving CYP3A4 Expression and Secretion via the EABR Motif.

Biomedicines·2026
Same author

40 Hz biparietal transcranial alternating current stimulation for Alzheimer's disease: a prospective study.

BMC medicine·2026
Same author

Current Status and Associated Factors of Discharge Readiness in Ambulatory-Surgery Patients Based on Transition Theory: A Cross-Sectional Study.

Nursing open·2026

Related Experiment Video

Updated: Sep 17, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.7K

Diffuse large B-cell lymphoma combined with two solid tumors: a case report.

Xiufang Zhang1, Shaojun Zhou1, Yuqiao Zhou2

  • 1Department of Oncology, The Second People's Hospital of Quzhou, Quzhou, China.

Frontiers in Oncology
|July 2, 2025
PubMed
Summary

This case study details a rare instance of a 67-year-old male diagnosed with three distinct cancers: diffuse large B-cell lymphoma (DLBCL), prostate cancer, and rectal cancer. The report highlights the successful management and long-term remission achieved through a multidisciplinary approach.

Keywords:
DLBCLmultiple primary malignant tumorsprostate cancerrectal cancersolid tumors

More Related Videos

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

3.3K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.3K

Related Experiment Videos

Last Updated: Sep 17, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.7K
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

3.3K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.3K

Area of Science:

  • Oncology
  • Hematology
  • Surgical Pathology

Background:

  • Multiple primary malignancies present unique diagnostic and therapeutic challenges.
  • Diffuse large B-cell lymphoma (DLBCL), prostate cancer, and rectal cancer are distinct neoplastic processes.

Observation:

  • A 67-year-old male initially presented with a lumbar spine tumor, diagnosed as DLBCL.
  • The patient subsequently developed prostate cancer and later, rectal cancer.
  • The patient experienced recurrence of DLBCL and achieved complete remission for all malignancies sequentially.

Findings:

  • This is the first reported case of triple primary malignancies involving DLBCL, prostate cancer, and rectal cancer.
  • A staged therapeutic strategy involving chemotherapy, radiotherapy, surgery, and targeted therapy was employed.
  • The patient achieved a second complete remission after DLBCL recurrence and successful treatment of rectal cancer.

Implications:

  • This case provides valuable clinical experience in managing rare triple primary malignancies.
  • Multidisciplinary collaboration is crucial for optimizing treatment outcomes in complex oncological cases.
  • The successful application of R-CHOP, R-MTX-CHOP, R-GemOx, Orelabrutinib, and surgical interventions offers insights for similar rare presentations.